Moreover, ribociclib is associated with a lower incidence of grade ≥ 3 hematologic toxicity, grade ≥ 3 neutropenia, drug interruptions, and dose reductions, suggesting a more favorable safety profile than other CDK4/6 inhibitors. The gene discussed is CDK4; the disease is neutropenia.